Biotech developments to watch in 2026
2025 proved a turning point year for the biotech industry, albeit one wrought with contradiction. The post-COVID slump experienced by the industry seemed due to continue, with the sweeping cuts to the US health and research infrastructure implemented in January likely to have knock-on effects for the sector. However, advancements in, and excitement around, the use of AI in R&D and the continuing success of GLP-1 inhibitors – boosted by the US FDA’s approved expansion of semaglutide’s indications to include a suite of cardiovascular conditions – to name but a few factors, led to a resurgence in the biotech industry....
To view this content, please register now for access
Join our member community for FREE to access a collection of journal and online-only features, including:
- Exclusive access to educational videos, eBooks and insights into top BioTechniques journal articles
- The latest news and journal updates delivered straight to your inbox when you want it
- Personalized recommendations for the latest member-exclusive podcasts, interviews and expert opinions
- Priority registration to webinars, panel discussions and events
- Access to competitions and journal publication discounts, including 10% off open access fees when you sign up today!
You might also be interested in...